Aldeyra Therapeutics Announces Collaboration With the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients

LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX ) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will collaborate with the National Organization for Rare Disorders (NORD), a non-profit organization dedicated to helping people with rare diseases. Through this collaboration, Aldeyra and NORD will work to increase awareness of Sjögren-Larsson Syndrome (SLS) and provide patients with opportunities to connect with each other and to access information about their disease, available resources, and ongoing efforts related to diagnosis and treatment.

SLS is an orphan disease characterized by severely dry skin, retinal dysfunction, mental delay, and spasticity. Under the agreement, NORD will develop a multi-phased approach to enhance the ability of the SLS population to communicate and receive optimal care through development of a patient contact registry and other tools, such as social media. This will be conducted through RareLaunch™, NORD's capacity-building and mentor program, through which it works with rare disease patients to develop or evolve disease-specific communities for the purpose of sharing information, accessing resources and learning from medical experts.

Commenting on the agreement, Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, said, "NORD has been a leading voice for people suffering from rare disorders for over 30 years, helping to bring attention to patient populations that are often overlooked and have severe, unmet medical needs. This collaboration provides the opportunity to bridge a gap in awareness of Sjögren-Larsson Syndrome and will further our continued efforts to facilitate a more connected patient community and better educate physicians who could have patients with this condition."

Dr. Brady continued, "With Aldeyra's lead product candidate, NS2, approaching clinical testing, we believe there is an opportunity for significant advancement in how these patients are treated. We look forward to working with our partners at NORD to better understand patient needs and to providing patients with a greater knowledge of all current and future treatment options."

"SLS is a rare disease that has a significant impact on the quality of life of those who are afflicted, as well as their caretakers. We are pleased that Aldeyra is pursuing  a viable treatment option for this patient community," commented Peter L. Saltonstall, President and CEO of NORD. "We look forward to working with the Aldeyra team to help create further awareness of this disease and the needs of  patients living with it."

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to file Investigational New Drug applications for clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

About the National Organization for Rare Disorders

Established in 1983 by patient organization leaders providing advocacy for the Orphan Drug Act, NORD ( www.rarediseases.org ) is an independent, nonprofit organization representing the nearly 30 million Americans who have rare diseases, their families, and the patient organizations assisting them. With offices in Quincy, Massachusetts, Washington DC and Danbury, Connecticut, it provides programs of advocacy, education and research, as well as patient assistance programs to help patients obtain needed therapies.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; Aldeyra's ability to satisfy the conditions for the second tranche term loan and its ability to maintain compliance with its obligations under the Loan Agreement; Aldeyra's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov . Additional information will also be set forth in those sections of Aldeyra's quarterly report on Form 10-Q for the quarter ended September 30, 2014, which was filed with the SEC in the fourth quarter of 2014.

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results.  No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 125

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 396

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 192

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 92

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 89

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 0

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 272

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 0

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading

Top 5 Most Recently Viewed Articles

Inbank's Bond Offering Surpasses Expectations with High Demand

Updated Category News Views 193

Inbank's Successful Subordinated Bond Subscription Recently, Inbank wrapped up its public offering of subordinated bonds, marking a significant moment in the company's financial journey. The event attracted considerable attention, with an impressive 935 investors participating, ultimately subscribing to bonds worth a total of 21.6 million euros. This enthusiasm resulted...

Continue Reading
Investors Alert: Class Action Against Starbucks Corporation

Updated Category News Views 87

Class Action Filed Against Starbucks Corporation The Gross Law Firm is reaching out to investors of Starbucks Corporation (NASDAQ: SBUX) following significant financial announcements and issues raised concerning the company's recent performance. The Purpose Behind the Class Action This class action aims to provide shareholders who purchased SBUX stocks during the recently...

Continue Reading
Unlock Your Franchise Potential with Free UT Haslam Courses

Updated Category News Views 185

Revolutionizing Franchising Education The University of Tennessee's Haslam College of Business is proud to offer its franchising certification program without any fees, thanks to the generous support of successful entrepreneur Shelly Sun Berkowitz. As the founder and executive chairwoman of BrightStar Group Holdings Inc., Berkowitz brings invaluable experience to the...

Continue Reading
Ultra Maritime Launches New Facility to Enhance Naval Warfare Solutions

Updated Category News Views 257

Ultra Maritime Opens New Innovative Facility Today marks an exciting new chapter for Ultra Maritime as it inaugurates its latest integrated design and manufacturing center. This state-of-the-art facility is dedicated to supporting the evolving needs of global allied navies, particularly in anti-submarine warfare (ASW). The center, located in Greenford, UK, offers a modern...

Continue Reading
Exciting New Fundraising Initiative by Robin Hood for NYC

Updated Category News Views 395

Robin Hood Introduces a New Fundraising Venture In an exciting move that demonstrates their ongoing commitment to combating poverty, Robin Hood, New York's most extensive poverty-fighting organization, has launched a unique fundraising initiative titled 'The Robin Hood Pick-A-Ticker: A Fundraiser for Robin Hood (and your Favorite Charity!).' This initiative is made...

Continue Reading